Episode 36: Sofinnova Invetments' Jim Healy
BioVenture VoiCes with Chris Garabedian
00:00
Sofinnova's strategic shift to biotech
Jim describes funds four to seven, the decision to overweight biotech, and lessons from prior fund returns.
Play episode from 16:38
Transcript
